Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02444234 · ClinicalTrials.gov registry record · Phase 4
Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis
A Phase 4 study of Cystic Fibrosis, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT02444234 is a Phase 4 study of Cystic Fibrosis that has completed, run by University of Southern California. The registered enrollment target is 11 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02444234, a Phase 4 study of Cystic Fibrosis, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study is designed to characterize the pharmacokinetics of intravenous and oral tedizolid in patients with Cystic Fibrosis.
Conditions Studied
Interventions
- DRUG Tedizolid PO
- DRUG Tedizolid IV
Study Locations (1)
California
- University of Southern California - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-07 |
| Est. Completion | 2017-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02444234
The ClinicalTrials.gov registry entry for NCT02444234 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (94% lower). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Tedizolid PO is the first listed.
NCT02444234 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02444234 about?
NCT02444234 is a clinical study titled "Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis". The proposed study is designed to characterize the pharmacokinetics of intravenous and oral tedizolid in patients with Cystic Fibrosis.
What is the current status of trial NCT02444234?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2015-07. Estimated completion is 2017-12-31.
What conditions does trial NCT02444234 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT02444234?
The interventions under investigation include: Tedizolid PO (DRUG), Tedizolid IV (DRUG).
Who is sponsoring clinical trial NCT02444234?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02444234 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Markers of Osteoporosis in Cystic Fibrosis
RECRUITING · Phase 4
-
BEGIN Novel ImagiNG Biomarkers
RECRUITING · Phase 4
-
Estrogen Supplementation and Bone Health in Women With CF
RECRUITING · Phase 4
-
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
RECRUITING · Phase 4
-
Hyperpolarized Imaging for New Treatments
ACTIVE NOT RECRUITING · Phase 4
-
Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.